Comorbid patient with gastroesophageal reflux disease: Features of the choice of proton pump inhibitor

The high prevalence of gastroesophageal reflux disease (GERD) and ageing of the population makes the issue of GERD pharmacotherapy a challenge for a comorbid patient, taking into account the choice of an effective proton pump inhibitor (PPI) that has a stable and long-term acid suppression, metabolic neutrality and a low risk of drug interactions. The combination of classic esophageal manifestations of GERD, such as heartburn and regurgitation with extraesophageal manifestations due to high gastroesophageal reflux resulting in the development of ENT and respiratory symptoms, contributes to the complexity of issues of differential diagnosis and pharmacotherapy. The occurrence of chest pain and heart rhythm disturbances in a patient with GERD requires differentiation from cardiovascular diseases and the choice of therapy affecting all pathogenetic components in the context of comorbidity. Proton pump inhibitors as the mainstay of pharmacological acid suppression in GERD treatment regimens should be prescribed as the primary therapeutic course and part of maintenance therapy regimens, the duration of which is determined on a patient-by-patient basis and often amounts to years of use, which should take into account not only the effectiveness, but also the safety of a particular drug. Pantoprazole is a selective PPI for the gastric parietal cells, in which the pH reaches the lowest values, provides a long-term acid-reducing effect and is metabolically neutral when administered together with other drugs in comorbid patients. Evaluation of the safety of long-term use of the drug for up to 15 years based on the results of clinical studies showed the absence of a risk of malignant neoplasms. Moderate hypergastrinemia was not accompanied by clinically significant changes in the mucous membrane throughout the entire period of pantoprazole therapy. In conclusion, daily maintenance therapy with pantoprazole for up to 15 years is effective, well tolerated and does not raise safety concerns.

1. Clarrett DM, Hachem C. Gastroesophageal Reflux Disease (GERD). Mo Med. 2018;115(3):214–218. Available at: https://pubmed.ncbi.nlm.nih.gov/30228725/.

2. Sharma P, Yadlapati R. Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid. Ann N Y Acad Sci. 2021;1486(1):3–14. https://doi.org/10.1111/nyas.14501.

3. Ivashkin VT, Trukhmanov AS, Maev IV, Drapkina OM, Livzan MA, Martynov AI et al. Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111–135. (In Russ.) https://doi.org/10.22416/1382-4376-2024-34-5-111-135.

4. Maev IV, Yurenev GL, Burkov SG, Sergeeva TA. Bronchopulmonary and oropharyngeal manifestations of gastroesophageal reflux disease. Consilium Medicum. 2006;(2):22–27. (In Russ.) Available at: https://gastroscan.ru/literature/authors/1697.

5. Abdulmanapova DN, Chamsutdinov NU. Bronchopulmonary manifestations of gastroesophageal reflux disease: pathogenesis, clinical and diagnostic. Modern Problems of Science and Education. 2013;(2):17. (In Russ.) Available at: https://science-education.ru/ru/article/view?id=8611.

6. Rogliani P, Sforza M, Calzetta L. The impact of comorbidities on severe asthma. Curr Opin Pulm Med. 2020;26(1):47–55. https://doi.org/10.1097/MCP.0000000000000640.

7. Cazzola M, Rogliani P, Ora J, Calzetta L, Matera MG. Asthma and comorbidities: recent advances. Pol Arch Intern Med. 2022;132(4):16250. https://doi.org/10.20452/pamw.16250.

8. Perotin JM, Wheway G, Tariq K, Azim A, Ridley Robert A, Ward JA et al. Vulnerability to acid reflux of the airway epithelium in severe asthma. Eur Respir J. 2022;60(2):2101634. Published 2022 Aug 4. https://doi.org/10.1183/13993003.01634-2021.

9. Brew BK, Almqvist C, Lundholm C, Andreasson A, Lehto K, Talley NJ, Gong T. Comorbidity of atopic diseases and gastro-oesophageal reflux: evidence of a shared cause. Clin Exp Allergy. 2022;52(7):868–877. https://doi.org/10.1111/cea.14106.

10. Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019;151:43–48. https://doi.org/10.1016/j.rmed.2019.04.001.

11. Takada K, Matsumoto S, Kojima E, Iwata S, Okachi S, Ninomiya K et al. Prospective evaluation of the relationship between acute exacerbations of COPD and gastroesophageal reflux disease diagnosed by questionnaire. Respir Med. 2011;105(10):1531–1536. https://doi.org/10.1016/j.rmed.2011.03.009.

12. Shimizu Y, Dobashi K, Kusano M, Mori M. Different gastoroesophageal reflux symptoms of middle-aged to elderly asthma and chronic obstructive pulmonary disease (COPD) patients. J Clin Biochem Nutr. 2012;50(2):169–175. https://doi.org/10.3164/jcbn.11-75.

13. Kim J, Lee JH, Kim Y, Kim K, Oh YM, Yoo KH et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med. 2013;13:51. https://doi.org/10.1186/1471-2466-13-51.

14. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. https://doi.org/10.1136/gutjnl-2012-304269.

15. Kamble NL, Khan NA, Kumar N, Nayak HK, Daga MK. Study of gastrooesophageal reflux disease in patients with mild-to-moderate chronic obstructive pulmonary disease in India. Respirology. 2013;18(3):463–467. https://doi.org/10.1111/j.1440-1843.2012.02285.x.

16. Terada K, Muro S, Ohara T, Kudo M, Ogawa E, Hoshino Y et al. Abnormal swallowing reflex and COPD exacerbations. Chest. 2010;137(2):326–332. https://doi.org/10.1378/chest.09-0482.

17. Gross RD, Atwood CW Jr, Ross SB, Olszewski JW, Eichhorn KA. The coordination of breathing and swallowing in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(7):559–565. https://doi.org/10.1164/rccm.200807-1139OC.

18. Ward C, Forrest IA, Brownlee IA, Johnson GE, Murphy DM, Pearson JP et al. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. Thorax. 2005;60(10):872–874. https://doi.org/10.1136/thx.2004.036426.

19. Timms C, Thomas PS, Yates DH. Detection of gastro-oesophageal reflux disease (GORD) in patients with obstructive lung disease using exhaled breath profiling. J Breath Res. 2012;6(1):016003. https://doi.org/10.1088/1752-7155/6/1/016003.

20. Pandolfino JE, Kahrilas PJ. Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12(8):837–842. https://doi.org/10.1097/00042737-200012080-00002.

21. El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastrooesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther. 2009;29(5):470–480. https://doi.org/10.1111/j.1365-2036.2008.03901.x.

22. Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and risks. Int J Chron Obstruct Pulmon Dis. 2015;10:1935–1949. https://doi.org/10.2147/COPD.S77562.

23. Jung HK, Choung RS, Talley NJ. Gastroesophageal reflux disease and sleep disorders: evidence for a causal link and therapeutic implications. J Neurogastroenterol Motil. 2010;16(1):22–29. https://doi.org/10.5056/jnm.2010.16.1.22.

24. Linz D, Hohl M, Nickel A, Mahfoud F, Wagner M, Ewen S et al. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension. 2013;62(4):767–774. https://doi.org/10.1161/HYPERTENSIONAHA.113.01728.

25. Demeter P, Pap A. The relationship between gastroesophageal reflux disease and obstructive sleep apnea. J Gastroenterol. 2004;39(9):815–820. https://doi.org/10.1007/s00535-004-1416-8.

26. Chen CH, Lin CL, Kao CH. Association between gastroesophageal reflux disease and coronary heart disease: A nationwide population-based analysis. Medicine. 2016;95(27):e4089. https://doi.org/10.1097/MD.0000000000004089.

27. Teragawa H, Oshita C, Ueda T. History of gastroesophageal reflux disease in patients with suspected coronary artery disease. Heart Vessels. 2019;34(10):1631–1638. https://doi.org/10.1007/s00380-019-01413-1.

28. Castell DO. Chest pain of undetermined origin: overview of pathophysiology. Am J Med. 1992;92(5A):2S–4S. https://doi.org/10.1016/0002-9343(92)80049-6.

29. Oparin A, Vnukova A. The Role of Endothelial Dysfunction in the Mechanism of Gastroesophageal Reflux Disease Development in Patients with Ischemic Heart Disease. Acta Clin Croat. 2017;56(4):635–639. https://doi.org/10.20471/acc.2017.56.04.08.

30. Linz D, Hohl M, Vollmar J, Ukena C, Mahfoud F, Böhm M. Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction. Europace. 2017;19(1):16–20. https://doi.org/10.1093/europace/euw092.

31. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 2008;6(1):52–60. https://doi.org/10.2174/157016108783331295.

32. Khomenko L, Vnukova A, Dvoiashkina Y. Features of endothelial dysfunction in elderly persons with coronary heart disease and concomitant gastroesophageal reflux disease. Georgian Med News. 2019;(287):78–82. Available at: https://pubmed.ncbi.nlm.nih.gov/30958293/.

33. Mungan Z, Pınarbaşı Şimşek B. Which drugs are risk factors for the development of gastroesophageal reflux disease?. Turk J Gastroenterol. 2017;28(Suppl 1):S38–S43. https://doi.org/10.5152/tjg.2017.11.

34. Gillinov AM, Rice TW. Prandial atrial fibrillation: off-pump pulmonary vein isolation with hiatal hernia repair. Ann Thorac Surg. 2004;78(5):1836–1838. https://doi.org/10.1016/S0003-4975(03)01434-6.

35. Bordin DS. How to select a proton pump inhibitor to a patient with GERD? Experimental and Clinical Gastroenterology. 2010;(2):53–58. (In Russ.) Available at: https://gastroscan.ru/literature/authors/4602.

36. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–534. https://doi.org/10.1007/s11894-008-0098-4.

37. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317–323. https://doi.org/10.1111/j.1523-5378.2007.00508.x.

38. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447–460. https://doi.org/10.1080/17425255.2018.1461835.

39. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–329. https://doi.org/10.1038/ajg.2012.444.

40. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007.

41. Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS ONE. 2013;8(12):e82562. https://doi.org/10.1371/journal.pone.0082562.

42. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295. https://doi.org/10.1080/03602530902843483.

43. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–260. https://doi.org/10.1016/j.jacc.2007.06.064.

44. Jonaitis P, Jonaitis L, Kupcinskas J. Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Helicobacter pylori Eradication Regimens. Curr Drug Metab. 2020;21(11):830–837. https://doi.org/10.2174/1389200221666200514081442.

45. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36(1):37–47. https://doi.org/10.1111/j.1365-2036.2012.05106.x.

46. Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–1174. https://doi.org/10.1111/apt.13194.

47. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682–691.e2. https://doi.org/10.1053/j.gastro.2019.05.056.